KPV - Longlife Peptides

Mechanism, Dosing, Effects

KPV (Lysine–Proline–Valine) is a short tripeptide fragment derived from α-MSH (alpha-melanocyte-stimulating hormone). It retains strong anti-inflammatory properties without causing skin darkening or melanotropic effects. KPV is widely studied for immune modulation, gut inflammation, and systemic inflammatory conditions.

Mechanism of Action

KPV works by:

Inhibiting NF-κB signaling (key inflammatory pathway)
Reducing production of:
- TNF-α
- IL-6
- IL-1β
Modulating immune cell activity
Stabilizing inflammatory responses
Supporting tissue repair

Unlike full α-MSH, KPV does NOT affect pigmentation, making it safer for long-term inflammatory modulation.

Dosing Strategy

Route: Subcutaneous
Vial: 10 mg

Reconstitution

Add 3.0 mL bacteriostatic water
Concentration: 3.33 mg/mL
U-100 syringe reference:
- 1 unit (0.01 mL) ≈ 33.3 mcg

Standard Titration Protocol

Week	Daily Dose	Syringe Units
Week 1	200 mcg	6 units (0.06 mL)
Week 2	300 mcg	9 units (0.09 mL)
Week 3	400 mcg	12 units (0.12 mL)
Weeks 4–8	500 mcg	15 units (0.15 mL)

Frequency: Once daily
Cycle length:

Standard: 8–12 weeks
Optional: Up to 16 weeks

Effects and Outcomes

Observed in research:

Strong anti-inflammatory action
Reduced systemic cytokines
Improved gut inflammation markers
Support for:
- IBS / IBD models
- Colitis
- Autoimmune pathways
Enhanced wound healing
Immune system modulation
No hormonal interference

Safety and Tolerability

Generally very well tolerated

Possible side effects

Mild injection-site redness
Slight swelling
Rare headache

Safety profile

No melanotropic effects
No hormonal suppression
Non-toxic in research dosing
Suitable for longer cycles
Rotate injection sites

Summary

KPV is a powerful anti-inflammatory peptide derived from α-MSH, working through immune modulation and cytokine suppression. A daily dose of 200–500 mcg for 8–12 weeks provides systemic inflammation control without pigmentation or hormonal effects.

Go Back